ChiCTR2600124074 版本V1.0 版本创建时间2026/05/07 10:35:08 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2600124074 

最近更新日期:

Date of Last Refreshed on:

2026-05-07 10:34:51 

注册时间:

Date of Registration:

2026-05-07 00:00:00 

注册号状态:

补注册

Registration Status:

Retrospective registration

注册题目:

经颈自体脂肪注射比较硅胶植入甲状软骨成形术改善单侧声带麻痹患者的喉功能的研究

Public title:

A comparative study of Transcervical Autologous Fat Injection versus Silicone Implant Thyroplasty for Improving Laryngeal Function in Patients with Unilateral Vocal Cord Paralysis

注册题目简写:

English Acronym:

研究课题的正式科学名称:

经颈自体脂肪注射比较硅胶植入甲状软骨成形术改善单侧声带麻痹患者的喉功能的研究

Scientific title:

A comparative study of Transcervical Autologous Fat Injection versus Silicone Implant Thyroplasty for Improving Laryngeal Function in Patients with Unilateral Vocal Cord Paralysis

研究课题代号(代码):

Study subject ID:

2024-2-23

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

王研 

研究负责人:

葛平江 

Applicant:

Yan Wang 

Study leader:

Pingjiang Ge 

申请注册联系人电话:

Applicant telephone:

+86 20 3397 1874

研究负责人电话:

Study leader's
telephone:

+86 137 5175 3465

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

wangyan@gdph.org.cn

研究负责人电子邮件:

Study leader's E-mail:

gepingjiang@gdph.org.cn

申请单位网址(自愿提供):

Applicant website(voluntary supply):

上海眼耳鼻喉科医院

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

广州市越秀区中山二路106号

研究负责人通讯地址:

广州市越秀区中山二路106号

Applicant address:

No.106, Ave Zhongshan Second,Guangzhou, 510080, China

Study leader's address:

No.106, Ave Zhongshan Second,Guangzhou, 510080, China

申请注册联系人邮政编码:

Applicant postcode:

510080

研究负责人邮政编码:

Study leader's postcode:

510080

申请人所在单位:

广东省人民医院

Applicant's institution:

Guangdong Provincial People's hospital

研究负责人所在单位:

广东省人民医院

Affiliation of the Leader:

Guangdong Provincial People's hospital

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

KY2024-206-02; KY2024-206-03

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

广东省人民医院伦理审查委员会

Name of the ethic committee:

Ethics Committee of Guangdong Provincial People's Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2024-02-27 00:00:00

伦理委员会联系人:

姚丽明

Contact Name of the ethic committee:

Liming Yao

伦理委员会联系地址:

广州市越秀区东华南路98号海印中心23楼

Contact Address of the ethic committee:

23/F, Haiyin Center, No. 98 Donghua South Road, Yuexiu District, Guangzhou, P.R.China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 20 8352 5975

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

广东省人民医院

Primary sponsor:

Guangdong Provincial People's hospital

研究实施负责(组长)单位地址:

No.106, Ave Zhongshan Second,Guangzhou, 510080, China

Primary sponsor's address:

Guangdong Provincial People's hospital

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

广东省

市(区县):

广州市

Country:

China

Province:

Guangdong

City:

Guangzhou

单位(医院):

广东省人民医院

具体地址:

广州市越秀区中山二路106号

Institution
hospital:

Guangdong Provincial People's hospital

Address:

No. 106, Zhongshan 2 Ave, Yuexiu County, Guangzhou City

经费或物资来源:

研究者发起的研究

Source(s) of funding:

Investigator-initiated Trial

研究疾病:

声带麻痹  

Target disease:

Vocal fold paralysis

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

治疗新技术临床试验 

Study phase:

New Treatment Measure Clinical Study

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

本研究拟研究经颈自体脂肪注射比较硅胶植入甲状软骨成形术改善单侧声带麻痹患者的喉功能,包括嗓音和吞咽功能改善情况,了解两种手术的疗效差异。  

Objectives of Study:

This study aims to compare the effects of transcervical autologous fat injection and silicone implant thyroplasty on improving laryngeal function, including voice and swallowing function, in patients with unilateral vocal cord paralysis, and to understand the differences in efficacy between the two surgical methods.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.年龄18-80岁。 2.有嗓音异常且要求手术治疗的患者。 3.通过电子喉镜检查发现有声带麻痹且病史超过9个月的患者。 4.通过嗓音障碍指数评估和听主观评估发现有嗓音异常的患者。 5.伴有或不伴有吞咽误吸或呛咳的患者。 6.同意参加本试验, 并已签署知情同意书。

Inclusion criteria

1. Aged 18-80 years. 2. Patients with voice abnormalities who require surgical treatment. 3. Patients diagnosed with vocal cord paralysis via electronic laryngoscopy with a medical history of more than 9 months. 4. Patients with voice abnormalities identified by Voice Handicap Index (VHI) assessment and auditory subjective assessment. 5. Patients with or without swallowing aspiration or choking. 6. Patients who agree to participate in this trial and have signed the informed consent form.

排除标准:

1. 没有意愿需要手术治疗的患者。 2. 不能配合完成喉镜检查及嗓音评估的患者。 3. 有严重心肺疾病不能完成手术的患者。 4. 病情较重,基本生活均不能自理。 5. 术前有喉部的手术病史。

Exclusion criteria:

1. Patients who do not wish to undergo surgical treatment. 2. Patients who cannot cooperate with laryngoscopy and voice assessment. 3. Patients with severe cardiopulmonary diseases who cannot tolerate surgery. 4. Patients with severe conditions who cannot take care of themselves in daily life. 5. Patients with a history of laryngeal surgery before this trial.

研究实施时间:

Study execute time:

From 2024-03-01 00:00:00 To 2027-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2024-03-01 00:00:00 To 2025-07-07 00:00:00

干预措施:

Interventions:

组别:

甲状软骨成形术

样本量:

21

Group:

Thyroplasty type 1

Sample size:

干预措施:

甲状软骨成形术I型:患者仰卧,颈丛麻醉,颈部皮肤横切口,暴露甲状软骨,在甲状软骨前下部位开窗,使用硅胶(Montgomery品牌)植入窗内固定,放置引流后关闭切口。

干预措施代码:

Intervention:

1.Patients are placed in a supine position under cervical plexus anesthesia. A transverse incision is made on the neck skin to expose the thyroid cartilage. A window is created in the anterior-inferior part of the thyroid cartilage, and a silicone implant (Montgomery brand) is placed and fixed in the window. A drain is placed, and the incision is closed.

Intervention code:

组别:

脂肪注射组

样本量:

21

Group:

Fat Injection

Sample size:

干预措施:

患者仰卧,全麻后下腹部切口切取5ml左右脂肪,切碎后滴入4u胰岛素和5mg的地塞米松,再用支撑喉镜暴露声门,在监视内镜下从颈部皮肤环甲膜黏膜下注射脂肪入声门旁间隙中,注射量2mL左右,手术后询问患者的有无咽痛、味觉变化等

干预措施代码:

Intervention:

2.Autologous Fat Injection: Patients are placed in a supine position under general anesthesia. Approximately 5 ml of fat is harvested from the lower abdomen via an incision. The fat is minced and mixed with 4 units of insulin and 5 mg of dexamethasone. The glottis is exposed using a laryngoscope, and the fat is injected into the paraglottic space under endoscopic guidance via the cricothyroid membrane submucosa through the neck skin, with an injection volume of approximately 2 mL. After surgery, patients are asked about symptoms such as sore throat and taste changes.

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

广东省 

市(区县):

广州市 

Country:

China

Province:

Guangdong

City:

Guangzhou

单位(医院):

广东省人民医院 

单位级别:

三甲 

Institution
hospital:

Guangdong Provincial People's hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

北京 

市(区县):

北京 

Country:

China

Province:

Beijing

City:

Beijing

单位(医院):

解放军总医院 

单位级别:

三甲 

Institution
hospital:

The General Hospital of the People's Liberation Army

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

嗓音障碍指数

指标类型:

主要指标

Outcome:

Voice handicap index

Type:

Primary indicator

测量时间点:

术后3-12月

测量方法:

问卷

Measure time point of outcome:

3-12 month after surgery

Measure method:

questionnaire

指标中文名:

喉镜评估

指标类型:

次要指标

Outcome:

laryngoscope

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

听主观评估

指标类型:

次要指标

Outcome:

perceptual assessment

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

最大发音时程

指标类型:

次要指标

Outcome:

maximum phonation duration

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

嗓音分析

指标类型:

次要指标

Outcome:

acoustic analysis

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

吞咽障碍评估量表

指标类型:

附加指标

Outcome:

Eating Assessment Tool

Type:

Additional indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

none

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

结束

/Completed

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 80 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

由本研究的数据管理员使用SPSS 26.0统计软件的随机数生成器,在研究开始前一次性生成1-42的随机数字序列(42为总样本量),按照随机数字从小到大的顺序,将前N例分配至试验组,剩余N例分配至对照组。随机序列生成后由独立第三方保存,研究者仅知晓分组编号,不知晓分组规则。

Randomization Procedure (please state who generates the random number sequence and by what method):

A random number sequence ranging from 1 to 42 (total sample size) will be generated in a single run prior to study initiation by the data manager using the random number generator function in SPSS 26.0. Subjects will be assigned to the experimental group (first N cases) or control group (remaining N cases) based on ascending order of random numbers. The generated sequence will be held by an independent third party, with investigators only informed of group assignments without access to the randomization schema.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

本研究对数据统计分析人员实施盲法。

Blinding:

Blinding will be implemented for the data statistical analysts in this study.

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

2028年1月1日;邮件联系研究负责人合理获取。

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

January 1, 2028; Contact the research leader via email to obtain reasonable information.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

A standard data collection

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2026-05-07 10:34:51